139 related articles for article (PubMed ID: 17538093)
1. HSV therapy and HIV-1 reduction.
Martinez V; Caumes E
N Engl J Med; 2007 May; 356(22):2323; author reply 2324. PubMed ID: 17538093
[No Abstract] [Full Text] [Related]
2. HSV therapy and HIV-1 reduction.
Eisenhut M
N Engl J Med; 2007 May; 356(22):2323-4; author reply 2324. PubMed ID: 17542070
[No Abstract] [Full Text] [Related]
3. A missed point in deciphering the viral synergy between herpes simplex virus and HIV.
Lisco A; Vanpouille C; Margolis L
Lancet Infect Dis; 2009 Sep; 9(9):522-3. PubMed ID: 19695487
[No Abstract] [Full Text] [Related]
4. Time to refocus on HSV interventions for HIV prevention?
Tanton C; Abu-Raddad LJ; Weiss HA
J Infect Dis; 2011 Dec; 204(12):1822-6. PubMed ID: 21998480
[No Abstract] [Full Text] [Related]
5. Herpes treatment may limit HIV transmission and progression.
Wilkinson E
Lancet Infect Dis; 2007 Apr; 7(4):249. PubMed ID: 17419138
[No Abstract] [Full Text] [Related]
6. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
[TBL] [Abstract][Full Text] [Related]
7. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.
Nagot N; Ouédraogo A; Foulongne V; Konaté I; Weiss HA; Vergne L; Defer MC; Djagbaré D; Sanon A; Andonaba JB; Becquart P; Segondy M; Vallo R; Sawadogo A; Van de Perre P; Mayaud P;
N Engl J Med; 2007 Feb; 356(8):790-9. PubMed ID: 17314338
[TBL] [Abstract][Full Text] [Related]
8. HSV-2 suppression reduces HIV and HSV shedding.
Collins S
GMHC Treat Issues; 2005 Dec; 19(12):11. PubMed ID: 16909510
[No Abstract] [Full Text] [Related]
9. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.
Tyring SK; Baker D; Snowden W
J Infect Dis; 2002 Oct; 186 Suppl 1():S40-6. PubMed ID: 12353186
[TBL] [Abstract][Full Text] [Related]
10. Fulminant hepatic failure secondary to acyclovir-resistant herpes simplex virus.
Shahani L
BMJ Case Rep; 2016 Oct; 2016():. PubMed ID: 27754940
[TBL] [Abstract][Full Text] [Related]
11. Short communication: T cell activation in HIV-1/herpes simplex virus-2-coinfected Kenyan women receiving valacyclovir.
Roxby AC; Liu AY; Drake AL; Kiarie JN; Richardson B; Lohman-Payne BL; John-Stewart GC; Wald A; De Rosa S; Farquhar C
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):94-8. PubMed ID: 22852760
[TBL] [Abstract][Full Text] [Related]
12. [Perspectives for the treatment and prevention of herpes simplex infections].
Snoeck R
Ann Dermatol Venereol; 2002 Apr; 129(4 Pt 2):662-5. PubMed ID: 12122338
[No Abstract] [Full Text] [Related]
13. The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2.
Van Wagoner N; Geisler WM; Bachmann LH; Hook EW
Int J STD AIDS; 2015 Jul; 26(8):574-81. PubMed ID: 25147236
[TBL] [Abstract][Full Text] [Related]
14. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.
Baeten JM; Strick LB; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Magaret A; Wald A; Corey L; Celum C
J Infect Dis; 2008 Dec; 198(12):1804-8. PubMed ID: 18928378
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous HSV-2 infection with serial recurrences at multiple sites.
Dacko A; Don PC; Weinberg JM
Int J Dermatol; 2002 Feb; 41(2):109-11. PubMed ID: 11982649
[No Abstract] [Full Text] [Related]
16. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.
Mugwanya K; Baeten JM; Mugo NR; Irungu E; Ngure K; Celum C
J Infect Dis; 2011 Dec; 204(12):1912-7. PubMed ID: 21998479
[TBL] [Abstract][Full Text] [Related]
17. Recent developments in the management of herpes simplex virus infection in HIV-infected persons.
Bartlett JG
Clin Infect Dis; 2004 Nov; 39 Suppl 5():S237-9. PubMed ID: 15494894
[No Abstract] [Full Text] [Related]
18. Trial shows HSV-2 suppression can reduce HIV shedding.
IAVI Rep; 2006; 10(1):20. PubMed ID: 16628770
[No Abstract] [Full Text] [Related]
19. HIV and STDs--oral manifestations.
Hammond L
Aust Fam Physician; 1997 Nov; 26(11):1346-7. PubMed ID: 9386323
[No Abstract] [Full Text] [Related]
20. Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial.
Tan DH; Raboud JM; Kaul R; Grinsztejn B; Cahn P; Walmsley SL
Trials; 2010 Nov; 11():113. PubMed ID: 21106086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
